AstraZeneca trips in PD-1 bispecific market after Phase III NSCLC failure
This setback marks a major blow to AstraZeneca as it strives to lead the wave of PD-1–based BsAbs in the treatment of solid tumours across Western markets.
This setback marks a major blow to AstraZeneca as it strives to lead the wave of PD-1–based BsAbs in the treatment of solid tumours across Western markets.